Evidence map›Paper›PMID 41808570›Full record

ReviewCancer2026

Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy.

David R Gandara, Mahmut Gümüş, Saadettin Kilickap, Ahmet Sezer, Igor Bondarenko, Mustafa Özgüroğlu, Miranda Gogishvili, Eric Yan, Xue Jia, Eric Kim and 2 more

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03088540 (A Global, Randomised, Phase 3, Open-label Study of REGN2810), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03088540 phase3completednot on this map

A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer

TypeinterventionalSponsorRegeneron PharmaceuticalsRan2017 to 2025Enrolled712ConditionsCarcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma, Nonsmall Cell Lung CancerArmsPemetrexed, Paclitaxel, Gemcitabine, Cisplatin, Carboplatin
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

David R GandaraDivision of Hematology and Oncology, Department of Medicine, University of California-Davis Comprehensive Cancer Center, Sacramento, California, USA.ORCID https://orcid.org/0000-0003-1784-048X
Mahmut GümüşDepartment of Medical Oncology, School of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.ORCID https://orcid.org/0000-0003-3550-9993
Saadettin KilickapDepartment of Medical Oncology, Istinye University Faculty of Medicine, Istanbul, Turkey.ORCID https://orcid.org/0000-0003-1637-7390
Ahmet SezerDepartment of Medical Oncology, Başkent University, Adana, Turkey.
Igor BondarenkoDepartment of Oncology and Medical Radiology, Dnipropetrovsk Medical University, Dnipro, Ukraine.
Mustafa ÖzgüroğluCerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
Miranda GogishviliHigh Technology Medical Centre, University Clinic Ltd., Tbilisi, Georgia.
Eric YanCyan Global, Inc., San Diego, California, USA.
Xue JiaParexel International, Durham, North Carolina, USA.
Eric KimRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Frank SeebachRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Ruben G W QuekRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.

Funding

Regeneron Pharmaceuticals, Inc.Sanofi
6 · The paper itself

Abstract

backgroundPatient-reported outcomes (PROs) for cemiplimab monotherapy versus chemotherapy from the EMPOWER-Lung 1 phase 3 clinical trial (ClinicalTrials.gov identifier NCT03088540) in patients who had advanced non-small cell lung cancer with programmed cell death-ligand 1 expression ≥50% were previously reported.

methodsThis review article characterizes PRO findings for cemiplimab monotherapy versus chemotherapy overall and in prespecified subgroups of patients from the EMPOWER-Lung 1 clinical trial. Patients were randomly assigned 1:1 to receive either cemiplimab 350 mg every 3 weeks or platinum-doublet chemotherapy, and multiple PROs, including the European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire, were administered in the EMPOWER-Lung 1 trial. PRO analyses using mixed model for repeated measures analysis to estimate least-squares mean changes in PRO scores from baseline and Cox proportional hazards models for the time to deterioration using a 10-point threshold have been reported and are summarized herein.

resultsGenerally, the mixed model for repeated measures analysis of global health status/quality of life (GHS/QoL) significantly favored cemiplimab versus chemotherapy in the overall study population and in prespecified subgroup populations. Statistically significant differences in the overall change from baseline in GHS/QoL favoring cemiplimab versus chemotherapy were observed overall and in multiple subgroups, including patients who had brain metastasis (p = .0110), an Eastern Cooperative Oncology Group performance status of 1 (p = .0017), squamous (p = .0247) and nonsquamous (p = .0073) histology, and patients aged 65 years and older (p = .0069). Statistically significant delays in the time to deterioration favoring cemiplimab were observed in GHS/QoL for the subgroup with programmed cell death-ligand 1 expression ≥90% (p = .0152) and the subgroup younger than 65 years (p = .0195).

conclusionsCollectively, the current data support the GHS/QoL benefit of first-line cemiplimab monotherapy versus chemotherapy overall and in multiple subpopulations of patients with programmed cell death-ligand 1 expression ≥50% advanced non-small cell lung cancer.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsPatient Reported Outcome MeasuresAgedB7-H1 AntigenFemaleHumansMaleMiddle AgedQuality of LifeRandomized Controlled Trials as TopicAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 Antigenadvanced non‐small cell lung cancercemiplimabimmunotherapypatient‐reported outcomesprogrammed cell death‐ligand 1 (PD‐L1)

Identifiers

PMID41808570
PMCPMC12976832

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.